Commitment fee for Glenmark under new crofelemer supply pact with Salix
This article was originally published in Scrip
Executive Summary
Glenmark has received the first tranche of a "commitment fee" from Salix Pharmaceuticals in view of the Indian firm's investment in and risks linked with upgrading its facility to raise the output of Napo Pharmaceuticals' anti-secretary gastrointestinal agent, crofelemer.